Collegium Pharmaceutical/$COLL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Ticker
$COLL
Sector
Primary listing
Employees
357
Headquarters
Website
COLL Metrics
BasicAdvanced
$1.2B
35.22
$1.06
0.68
-
Price and volume
Market cap
$1.2B
Beta
0.68
52-week high
$39.95
52-week low
$23.23
Average daily volume
461K
Financial strength
Current ratio
1.182
Quick ratio
1.092
Long term debt to equity
381.479
Total debt to equity
409.868
Interest coverage (TTM)
2.00%
Profitability
EBITDA (TTM)
375.765
Gross margin (TTM)
87.51%
Net profit margin (TTM)
5.13%
Operating margin (TTM)
23.24%
Effective tax rate (TTM)
31.56%
Revenue per employee (TTM)
$1,980,000
Management effectiveness
Return on assets (TTM)
7.76%
Return on equity (TTM)
16.16%
Valuation
Price to earnings (TTM)
35.224
Price to revenue (TTM)
1.688
Price to book
5.07
Price to tangible book (TTM)
-1.69
Price to free cash flow (TTM)
5.915
Free cash flow yield (TTM)
16.91%
Free cash flow per share (TTM)
6.309
Growth
Revenue change (TTM)
22.61%
Earnings per share change (TTM)
-56.36%
3-year revenue growth (CAGR)
31.14%
3-year earnings per share growth (CAGR)
0.99%
10-year earnings per share growth (CAGR)
-11.21%
What the Analysts think about COLL
Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
Bulls say / Bears say
Collegium reported record Q2 2025 net revenue of $188.0 million, up 29% year-over-year, driven by strong commercial execution across Jornay PM for ADHD as well as its pain medications (Collegium Press Release).
Management increased full-year 2025 guidance to $745–760 million in revenue and $440–455 million in adjusted EBITDA, showing confidence in sustained growth and strategic execution (Collegium Press Release).
The company generated $72.4 million in cash from operations and ended Q2 2025 with $222.2 million in cash, cash equivalents, and marketable securities. It also authorized a $150 million share repurchase program, demonstrating robust cash flow and a focus on shareholder returns (Collegium Press Release).
GAAP operating expenses soared 69% from last year to $73.3 million, while non-GAAP operating expenses climbed 104% to $61.9 million in Q2 2025, squeezing profitability (Collegium Press Release).
GAAP net income for Q2 2025 declined to $12.0 million from $19.6 million a year ago, with diluted EPS dropping to $0.34 from $0.52, signaling weaker earnings despite strong revenue growth (Collegium Press Release).
FDA approval of Vertex’s non-opioid painkiller Journavx increases competition for Collegium’s pain portfolio, and could erode market share for its opioid-based products over time (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
COLL Financial Performance
Revenues and expenses
COLL Earnings Performance
Company profitability
COLL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Collegium Pharmaceutical stock?
Collegium Pharmaceutical (COLL) has a market cap of $1.2B as of September 16, 2025.
What is the P/E ratio for Collegium Pharmaceutical stock?
The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 35.22 as of September 16, 2025.
Does Collegium Pharmaceutical stock pay dividends?
No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Collegium Pharmaceutical dividend payment date?
Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.
What is the beta indicator for Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.